Skip to main content

Alternative Credit News, Hedge Fund News, Private Equity News

General Atlantic Closes Sixth Flagship Growth Equity Fund

Growth equity firm General Atlantic has closed its sixth flagship fund, GA 2021, at $7.8bn, above its initial target of $5bn.

The firm, something of a pioneer in the growth equity asset class, now has $23.8bn in committed capital and over $78bn in assets under management, according to the firm. General Atlantic partners with high-growth, tech-enabled companies globally across five core sectors: Consumer, Financial Services, Healthcare, Life Sciences and Technology.

“Our global growth equity strategy positions us to capitalize on the profound acceleration of digital innovation and global entrepreneurship as we seek to deliver attractive risk-adjusted returns to our capital partners,” said Bill Ford, Chairman and CEO of General Atlantic. “Our ability to partner with management teams, help build rapidly growing, technology-enabled companies on a global scale, and generate strong and consistent investment performance distinguishes General Atlantic with both entrepreneurs and investors.”

“We believe that growth equity plays a critical role in driving innovation and delivering both strong performance and positive impact,” said Graves Tompkins, Managing Director and Global Head of Capital Partnering for General Atlantic. “The enthusiasm for our global investment strategy and partnership approach enables us to scale our capital base to meet our expanding opportunity set while creating strategic and long-term relationships with family and institutional investors.”

General Atlantic operates outside of the traditional fundraising cycle, with a capital structure that enables the firm to scale its capital base on an ongoing basis. The firm’s capital structure includes closed-end funds, five-year managed accounts and evergreen accounts, and A GP commitment, representing the largest single investor in GA’s core investing program.

Content role
Free

© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.